Issue 17, 2022

Correction: All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation

Abstract

Correction for ‘All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation’ by Xiao-xiao Guo et al., Nanoscale, 2021, 13, 14525–14537, https://doi.org/10.1039/D1NR03869A.

Associated articles

Article information

Article type
Correction
Submitted
08 Apr 2022
Accepted
08 Apr 2022
First published
25 Apr 2022
This article is Open Access
Creative Commons BY license

Nanoscale, 2022,14, 6670-6670

Correction: All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation

X. Guo, Z. Guo, J. Lu, W. Xie, Q. Zhong, X. Sun, X. Wang, J. Wang, M. Liu and L. Zhao, Nanoscale, 2022, 14, 6670 DOI: 10.1039/D2NR90081E

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements